Skip to main content
Top
Published in: Hepatology International 2/2009

01-06-2009 | Case Report

Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation

Authors: Soo Ryang Kim, Susumu Imoto, Taisuke Nakajima, Kenji Ando, Keiji Mita, Miyuki Taniguchi, Noriko Sasase, Toshiyuki Matsuoka, Masatoshi Kudo, Yoshitake Hayashi

Published in: Hepatology International | Issue 2/2009

Login to get access

Abstract

We describe three cases of well-differentiated hepatocellular carcinoma (HCC) smaller than 15 mm in diameter completely eradicated with percutaneous ethanol injection (PEI) instead of using radiofrequency ablation (RFA). Ultrasound (US) examination revealed one nodule each in segment 2 (hypoechoic, near bile ducts, 10 mm), in segment 5 (hyperechoic, near the gall bladder, 15 mm), and in segment 7 (hypoechoic, near the diaphragm, 15 mm). Although imaging studies revealed isovascular (case 1) and hypervascular (cases 2 and 3) nodules, histological analysis of US-guided biopsy tissue revealed well-differentiated HCC. In consideration of the location of the nodules, PEI, instead of RFA, was administered and the nodules were rendered necrotic. Although RFA is superior to PEI in the treatment of small HCCs from the viewpoint of treatment response and long survival, PEI is strongly recommended for HCCs located near bile ducts, the gall bladder, and the diaphragm, especially when the nodules are smaller than 15 mm in diameter.
Literature
1.
go back to reference Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503PubMedCrossRef
2.
go back to reference Okuda K, Peteres RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984;54:2165–2173PubMedCrossRef Okuda K, Peteres RL, Simson IW. Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer 1984;54:2165–2173PubMedCrossRef
3.
go back to reference Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557–1563PubMedCrossRef Trevisani F, Caraceni P, Bernardi M, D’Intino PE, Arienti V, Amorati P, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993;72:1557–1563PubMedCrossRef
5.
go back to reference Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–661PubMed Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655–661PubMed
6.
go back to reference Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130PubMedCrossRef Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122–130PubMedCrossRef
7.
go back to reference Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004;127:1714–1723PubMedCrossRef Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004;127:1714–1723PubMedCrossRef
8.
go back to reference Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapy. Hepatology 2009;49:453–459PubMedCrossRef Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapy. Hepatology 2009;49:453–459PubMedCrossRef
9.
go back to reference Kasugai H, Osaki Y, Oka H, Kudo M, Seki T, Osaka Liver Cancer Study Group. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. Oncology 2007;72:S72–S75CrossRef Kasugai H, Osaki Y, Oka H, Kudo M, Seki T, Osaka Liver Cancer Study Group. Severe complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3891 ablations in 2614 patients. Oncology 2007;72:S72–S75CrossRef
10.
go back to reference Takeuchi H, Arata T, Takehara K, Shigeyasu K, Kanazawa T, Murata H, et al. A patient who developed diaphragmatic hernia one year after percutaneous radiofrequency ablation for hepatocellular carcinoma. Kanzo 2007;48:458–462CrossRef Takeuchi H, Arata T, Takehara K, Shigeyasu K, Kanazawa T, Murata H, et al. A patient who developed diaphragmatic hernia one year after percutaneous radiofrequency ablation for hepatocellular carcinoma. Kanzo 2007;48:458–462CrossRef
11.
go back to reference Tomonaga C, Kawano A, Taguchi Y, Matsunaga T, Maruyama T, Toyoshima S, et al. Two cases of diaphragmatic hernia following percutaneous radiofrequency ablation of hepatocellular carcinoma. Kanzo 2007;48:529–537CrossRef Tomonaga C, Kawano A, Taguchi Y, Matsunaga T, Maruyama T, Toyoshima S, et al. Two cases of diaphragmatic hernia following percutaneous radiofrequency ablation of hepatocellular carcinoma. Kanzo 2007;48:529–537CrossRef
12.
go back to reference Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987;60:810–819PubMedCrossRef Kanai T, Hirohashi S, Upton MP, Noguchi M, Kishi K, Makuuchi M, et al. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification. Cancer 1987;60:810–819PubMedCrossRef
13.
go back to reference Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101–105PubMed Nakashima O, Sugihara S, Kage M, Kojiro M. Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 1995;22:101–105PubMed
14.
go back to reference Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999;19:287–296PubMedCrossRef Kojiro M, Nakashima O. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumors. Semin Liver Dis 1999;19:287–296PubMedCrossRef
15.
go back to reference Kondo Y, Niwa Y, Akikusa B, Takazawa H, Okabayashi A. A histopathologic study of early hepatocellular carcinoma. Cancer 1983;52:687–692PubMedCrossRef Kondo Y, Niwa Y, Akikusa B, Takazawa H, Okabayashi A. A histopathologic study of early hepatocellular carcinoma. Cancer 1983;52:687–692PubMedCrossRef
16.
go back to reference Nakashima T, Kojiro M. Hepatocellular Carcinoma: An Atlas of its Pathology. Tokyo: Springer-Verlag; 1987 Nakashima T, Kojiro M. Hepatocellular Carcinoma: An Atlas of its Pathology. Tokyo: Springer-Verlag; 1987
17.
go back to reference Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353–357PubMedCrossRef Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353–357PubMedCrossRef
18.
go back to reference Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In Tabor E, editor. Viruses and Liver Cancer. Amsterdam: Elsevier; 2002. 113–122CrossRef Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In Tabor E, editor. Viruses and Liver Cancer. Amsterdam: Elsevier; 2002. 113–122CrossRef
19.
go back to reference Kojiro M. Pathology of Hepatocellular Carcinoma. Oxford: Blackwell; 2006. 39–49 Kojiro M. Pathology of Hepatocellular Carcinoma. Oxford: Blackwell; 2006. 39–49
20.
go back to reference Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008;14:1997–2002PubMedCrossRef Taniguchi M, Kim SR, Imoto S, Ikawa H, Ando K, Mita K, et al. Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular carcinoma. World J Gastroenterol 2008;14:1997–2002PubMedCrossRef
Metadata
Title
Well-differentiated hepatocellular carcinoma smaller than 15 mm in diameter totally eradicated with percutaneous ethanol injection instead of radiofrequency ablation
Authors
Soo Ryang Kim
Susumu Imoto
Taisuke Nakajima
Kenji Ando
Keiji Mita
Miyuki Taniguchi
Noriko Sasase
Toshiyuki Matsuoka
Masatoshi Kudo
Yoshitake Hayashi
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 2/2009
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9128-z

Other articles of this Issue 2/2009

Hepatology International 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine